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Abstract
In eukaryotic cells an uncleavable ubiquitin moiety conjugated to the N-terminus of a protein signals the degradation of the
fusion protein via the proteasome-dependent ubiquitin fusion degradation (UFD) pathway. In yeast the molecular
mechanism of the UFD pathway has been well characterized. Recently the human E3 ubiquitin-protein ligase TRIP12 was
connected with the UFD pathway, but little is otherwise known about this system in mammalian cells. In the present work,
we utilized high-throughput imaging on cells transfected with a targeted siRNA library to identify components involved in
degradation of the UFD substrate UbG76V-YFP. The most significant hits from the screen were the E3 ubiquitin-protein ligase
HUWE1, as well as PSMD7 and PSMD14 that encode proteasome subunits. Accordingly, knock down of HUWE1 led to an
increase in the steady state level and a retarded degradation of the UFD substrate. Knock down of HUWE1 also led to
a stabilization of the physiological UFD substrate UBB+1. Precipitation experiments revealed that HUWE1 is associated with
both the UbG76V-YFP substrate and the 26S proteasome, indicating that it functions late in the UFD pathway. Double knock
down of HUWE1 and TRIP12 resulted in an additive stabilization of the substrate, suggesting that HUWE1 and TRIP12
function in parallel during UFD. However, even when both HUWE1 and TRIP12 are downregulated, ubiquitylation of the
UFD substrate was still apparent, revealing functional redundancy between HUWE1, TRIP12 and yet other ubiquitin-protein
ligases.
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Introduction
The ubiquitin-proteasome system (UPS) is responsible for the
majority of intracellular protein degradation, and also plays an
important regulatory role in many cellular processes, including
metabolism, cell division, DNA repair, antigen presentation, signal
transduction, and development [1].
With few exceptions, proteins must be conjugated to a chain of
ubiquitin before they become substrates for the 26S proteasome.
The conjugation reaction relies on a cascade of three enzymes,
termed E1, E2, and E3 that conjugate the small protein ubiquitin
to specific target proteins [1]. In this enzyme cascade the
ubiquitin-activating enzyme (E1) first activates ubiquitin in an
ATP-dependent reaction by forming a thioester bond with the C-
terminal glycine residue (G76) in ubiquitin. Ubiquitin is then
transferred to the ubiquitin-conjugating enzyme (E2) before
a ubiquitin-protein ligase (E3) transfers ubiquitin to a lysine
residue in the target protein. Ubiquitin can also be transferred to
a lysine residue in ubiquitin already attached to the target protein,
thus forming a chain of ubiquitin moieties. In some cases the
ubiquitin chain on the target protein may be elongated by an E4
ubiquitin-chain elongation factor [2].
Depending on their enzymatic domains and reaction mecha-
nism, E3s are generally classified into two major families: RING
(really interesting new gene) domain E3s and HECT (homologous
to E6AP C-terminus) domain E3s. The HECT domain E3s
normally contain a diverse N-terminal region and a conserved C-
terminal HECT domain. The HECT domain contains a reactive
cysteine residue that forms a transient thioester bond to the
ubiquitin C-terminal carboxyl group before transfer of the
ubiquitin moiety to the target protein [3]. RING domains, on
the other hand, do not form covalently-linked intermediates with
ubiquitin during the reaction.
The process of ubiquitylation is reversible, and the human
genome encodes around 100 different deubiquitylating enzymes
(DUBs), which can all potentially trim or release ubiquitin chains
conjugated to target proteins [4].
The proteins that have been marked with polyubiquitin are
targeted to the 26S proteasome, a large and abundant proteolytic
particle found in the nucleus and cytosol of all eukaryotic cells [5].
At the 26S proteasome, the ubiquitin chains can be further
elongated or released, while the substrate is degraded into shorter
peptides that can be displayed on the cell surface for immuno
surveillance or further degraded to free amino acids by various
amino peptidases [6].
Although it was first described in yeast [7] [2], the ubiquitin
fusion degradation (UFD) pathway is conserved in all eukaryotic
cells [8]. In this proteolytic system, an uncleavable ubiquitin
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moiety, fused to the N-terminus of a protein, signals rapid
degradation of the fusion protein. Elegant studies have defined the
key components of this pathway in the budding yeast, Saccharomyces
cerevisiae [7] [2]. Ubiquitylation is catalyzed by the HECT domain
E3, called Ufd4 [9], while ubiquitin chain elongation is performed
by the E4, Ufd2 [2]. In addition, the UFD pathway requires the
AAA (ATPase associated with various cellular activities) ATPase,
called Cdc48 in yeast and p97 or VCP in mammals, and the p97/
Cdc48 co-factors Ufd1 and Ufd3 [7] [10]. So far most studies on
the UFD system have utilized artificial model substrates. However,
more recently the human orthologue of budding yeast Ufd4, called
TRIP12, was shown to participate in the UFD pathway and
mediate degradation of UBB+1, a physiological UFD substrate
[11]. UBB+1 is a frame shift mutant ubiquitin derived from
a dinucleotide deletion in the mRNA of the ubiquitin B gene,
leading to an uncleavable N-terminal ubiquitin moiety linked to
a short C-terminal extension [12]. In patients with neurodegen-
erative disorders, including Alzheimer’s diseases and various
polyglutaminopathies, UBB+1 accumulates in brain tissue [13].
Studies have shown that high levels of UBB+1 inhibits the UPS and
leads to cell cycle arrest [14]. Thus, high concentrations of UBB+1
will most likely contribute to an environment that favors
accumulation of misfolded proteins and in this manner further
aggravate the disease. However, at lower levels UBB+1 is efficiently
cleared via the UFD pathway [14–15] [11].
To determine if other cellular E3s collaborate with TRIP12 in
the degradation of UFD substrates, we utilized a targeted siRNA
screen to identify novel components involved in degradation of the
ubiquitin fusion protein UbG76V-YFP. The most significant hits
from the screen included the E3 ubiquitin-protein ligase HUWE1
and 26S proteasome subunits. Accordingly, knock down of
HUWE1 led to a retarded degradation of the UbG76V-YFP and
UBB+1 substrates. Since we could co-precipitate HUWE1 with the
substrate and the 26S proteasome, we propose that HUWE1
directly ubiquitylates UFD substrates at a late step during the
degradation pathway.
Materials and Methods
Buffers, Plasmids and Antibodies
Buffer A, 25 mM Tris/HCl pH 7.5, 2 mM MgCl2, 2 mM
ATP, 50 mM NaCl, 1 mM DTT, 10% (v/v) glycerol, 0.1% (v/v)
Triton X-100.
Plasmids for expression of flag-tagged UBB+1 were generously
supplied by Prof. Yoon, Yonsei University, Korea.
The antibodies to p97 have been described previously [16].
Antibodies to human proteasomes were purchased from Enzo.
The anti-GFP, anti-flag and anti-b-actin antibodies were pur-
chased from Sigma. Antibodies to HUWE1 have been described
previously [17] and were kindly supplied by Prof. Wing, McGill
University, Canada. All secondary antibodies were purchased
from Dako.
Cell Culture
MelJuso cells, stably transfected to express ubiquitin-G76V-YFP
[18], were maintained in Dulbecco’s modified eagle’s media
(DMEM) containing 10% fetal bovine serum (Biosera), and
supplemented with glutamine, penicillin/streptomycin and
0.25 mg/ml geneticin at 37uC in a humidified atmosphere
containing 7.5% CO2.
Electrophoresis and Blotting
Proteins were separated on 7 cm 6 8 cm 12.5% or 8%
acrylamide gels. Proteins were transferred to BA83 (Schleicher &
Schuell) nitrocellulose membranes and probed with antibodies as
indicated.
Transfection
Interfering RNAs specific for human HUWE1, TRIP12 and
p97 were purchased as either siRNA #1 ON-TARGETplus
SMARTpool from Thermo scientific (HUWE1: J-00718507, J-
00718508, J-00718509, J-00718510. TRIP12: J-00718206, J-
00718207, J-00718208, J-00718209. VCP/p97: D-00872705, D-
00872706, D-00872707, D-00872708. Non-targeting pool: D-
00181010) or siRNA #2 FlexiTube siRNA (SI04336178) from
Qiagen. The siCONTROL siRNA#1 (Dharmacon) was used as
an unspecific control. Trypsinized cells were incubated for 48
hours with a solution containing 50 nM siRNA, 0.001%
lipofectamin RNAi MAX in 40% OptiMEM and 60% DMEM
supplemented with 10% fetal bovine serum.
Co-precipitations
For precipitation experiments Mel-Juso cells, stably transfected
to express UbG76V-YFP, were treated for 6 hours with 25 mM
MG132 and then lyzed by sonication in 4 volumes of buffer A.
Cleared extracts were prepared by centrifugation (12000 g,
30 min). The cleared lysates were incubated at 4uC for 4 hours
with gentle agitation with 0.25 mL anti-GFP (Sigma) or 1 mL anti-
MCP20 (Enzo) and 20 mL Protein G Sepharose beads (GE
Healthcare). As a negative control antibodies to a2-macroglobulin
were used. The beads were then washed in 3615 mL of buffer A
before elution in SDS sample buffer. The eluted material was
analyzed by SDS-PAGE and immunoblotting.
Protein Degradation Experiments
The stability of the UbG76V-YFP model substrate was followed
by pulse-chase analysis on stably transfected cells expressing the
substrate, as described previously [19]. The degradation of UBB+1
was followed by cycloheximide decay assays as described [11].
Reverse Transcription PCR
The knock down efficiency of TRIP12 was determined by
reverse transcription PCR. For this purpose mRNA was isolated
using TRIzol (Invitrogen) and Turbo DNA-free (Ambion). The
RNA was reverse transcribed using Transcriptor first strand
cDNA synthesis (Roche Applied Science), purified using
GFXPCRDNA (GE Healthcare), and used for PCR. GAPDH
was used as a negative control. The primers specific for GAPDH
were: forward, AGCCTCCCGCTTCGCTCTCT, reverse,
TGACCTTGGCCAGGGGTGCT. The primers specific for
TRIP12 were: forward, CCGGGGCCCAACCACAAGAC, re-
verse, TGGACGCTGAACGGGAACGC.
siRNA Screening
The siRNA library used was a customized Human Silencer
siRNA Library from Applied Biosystems. The library consists of
three individual siRNAs specific for 558 different gene products
predicted to play a role in the ubiquitin-proteasome system. A list
of all targets in the library can be found under supplementary
materials (Table S1).
The automated screen was performed using the MicrolabSTAR
liquid handling system (Hamilton Robotics). MelJuso cells were
reverse transfected with the customized siRNA library including
individual positive and negative controls. In brief, 4 mL siRNA was
added to 2.5 mL OptiMEM (Invitrogen) into each well of a 384-
well plate (Corning) (Fig. S1). To this, a 6.4 mL OptiMEM/0.1 mL
RNAiMAX (Invitrogen) mix was added and left for 15 min, after
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which 27 mL of cells were added to give a total cell density of
2400 cells per well. The final concentration of siRNA was 50 nM.
Cells were then incubated for 48 h or 72 h, followed by fixation
(Gurr histological fixative, VWR) and Hoechst staining (Sigma-
Aldrich). In addition, individual wells were treated with 25 mM
MG132 4 hours prior to fixation. Plates were imaged on an IN
Cell Analyzer 1000 (GE Healthcare) acquiring a minimum of 6
images per well using a 106 objective to count approximately
2000 cells per well.
Image Analysis and Statistics
Acquired images were analyzed using the IN Cell Analyzer
Workstation 3.6 software (GE Healthcare) and percentage of
ubiquitinG76V-YFP positive cells scored based on the overall
nuclear and cellular intensity. This data was then normalized to
the median sample score of each plate (excluding controls) and
a gene-based hit list was generated using the statistical method
‘‘redundant siRNA activity’’ (RSA) analysis [20]. The RSA
method first ranked individual siRNAs according to their
Figure 1. The proteasome and p97 are required for UbG76V-YFP degradation. (a) The steady state level of the UbG76V-YFP substrate was
determined by blotting extracts from cells treated with the proteasome inhibitor MG132 and siRNA to p97. Actin served as a loading control. (b)
Fluorescence microscopy of UbG76V-YFP (green) in cells treated with the proteasome inhibitor MG132 or siRNA to p97. Hoechst staining (blue) was
used to mark the nuclei. (c) Pulse-chase analyses of UbG76V-YFP degradation in cells transfected with control siRNA or siRNA specific for p97.
doi:10.1371/journal.pone.0050548.g001
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normalized scores (excluding controls) and then calculated p-
values for each gene based on the likelihood for this distribution of
siRNA ranks to occur by chance. This calculation of p-values was
based on the iterative hypergeometric distribution [20]. Sub-
sequently, RSA-based p-values of the three individual screens were
combined using Fisher’s combined probability test. The entire
statistical analysis was conducted using the statistical software ‘R’.
Results
p97 is Required for Degradation of UbG76V-YFP
To study the UFD pathway, cells stably transfected to express
the ubiquitin-G76V-YFP fusion protein (UbG76V-YFP) were used
[18]. In these cells, the steady-state level of the UbG76V-YFP
substrate was very low. By Western blotting using antibodies to
GFP, we were unable to detect the UbG76V-YFP protein in
unperturbed cells (Fig. 1a). However, upon addition of the
proteasome inhibitor MG132, a clear signal at about 35 kDa,
corresponding to ubiquitin (,8 kDa) and YFP (,25 kDa), was
obtained (Fig. 1a). This suggests that the low cellular level of the
UbG76V-YFP protein was due to rapid proteasomal degradation.
By fluorescence microscopy, the UbG76V-YFP protein was also
undetectable in unperturbed cells, but again the level increased
dramatically upon treatment with MG132 (Fig. 1b). In accordance
with previous results [18], the fluorescent signal of UbG76V-YFP
appeared somewhat stronger in the nucleus than in the cytosol
(Fig. 1b).
Since the AAA-type ATPase p97 is critical for degradation of
many proteasome substrates, we also tested if knock down of p97
led to an increased level of the UbG76V-YFP substrate protein.
Indeed, we observed a robust increase in the UbG76V-YFP level
upon p97 knock down, both by Western blotting and by
fluorescence microscopy (Fig. 1a and 1b). To determine the
degradation kinetics of the UFD substrate, we performed pulse-
chase analyses on cells transfected with siRNA to p97. In cells
transfected with control siRNA we found that UbG76V-YFP was
rapidly degraded (Fig. 1c). As expected, p97 knock down strongly
Figure 2. Results from the siRNA screens. (a) The 558 different genes assayed in the screen ranked according to the p-values assigned to each
gene using the RSA analysis and the Fisher’s probability test. Each gene is assigned a single p-value based on the ranking distribution of all three
siRNAs in three individual screening experiments. (b) The genes scoring a combined p-value below 5% are ranked.
doi:10.1371/journal.pone.0050548.g002
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inhibited degradation (Fig. 1c), showing that p97 is critical for
degradation of UbG76V-YFP.
Identification of Novel UFD Pathway Components by
siRNA Screening
Since knock down of p97 led to a strong increase in the UbG76V-
YFP level, it was ideally suited as a positive control for a targeted
siRNA screen. A customized siRNA library consisting of three
individual siRNAs to each of 558 different gene products,
predicted to play a role in the ubiquitin system (Table S1), was
therefore reverse transfected into the reporter cell line. An siRNA
targeting p97 and MG132 treatment were included as positive
controls, whilst scrambled siRNA served as a negative control.
After 48 or 72 hours the cells were fixed and the percentage of
cells showing a YFP signal was monitored for each transfection by
automated fluorescence microscopy. By subsequent image analy-
sis, the percentage of cells displaying YFP signal was determined
and plate-wise normalized. We observed no significant differences
between the 48 and 72 hour transfection periods (Fig. S2). To
minimize the risk of false scoring based on off-target effects of
individual siRNAs, we computed a statistical score that modeled
the probability of a gene ‘hit’ based on the collective activities of all
three siRNAs per gene using the statistical method ‘‘redundant
siRNA activity’’ (RSA) analysis [20]. Thus, RSA analysis scored
genes based on a combined p-value of all siRNAs per gene. P-
values of the three individual screens were then further combined
to a common p-value based on Fisher’s probability test (Fig. 2a
and Table S1). In total 19 genes, corresponding to about 3% of the
library, scored significantly (Table 1). In addition to the p97
transfection control (Fig. S2), proteasome subunits PSMD7 and
PSMD14 scored highly significant (Fig. 2b), suggesting that the
screening approach worked. Another significant hit was the E3
ubiquitin-protein ligase HUWE1 (Fig. 2b).
Slowed UbG76V-YFP Degradation upon Knock Down of
HUWE1
If HUWE1 identified from the siRNA screening indeed partakes
in the degradation of the UFD substrate, one would expect that
the degradation kinetics of the UbG76V-YFP protein are slowed
when HUWE1 is knocked down. To test this and thus verify the
result of the high-throughput cellular imaging, pulse-chase
experiments were performed.
Upon knock down of HUWE1, we observed a clear reduction in
the cellular level of the HUWE1 protein (Fig. 3a). Since we were
unable to obtain functional antibodies to TRIP12, successful
depletion of this component was analyzed by RT-PCR (Fig. 3a).
When expression of HUWE1, or as controls TRIP12 and p97,
were knocked-down the steady-state level of the UbG76V-YFP
protein was increased (Fig. 3b). Accordingly, we observed that
UbG76V-YFP degradation upon knock down of HUWE1 was
slowed (Fig. 3c). HUWE1, like TRIP12, is a HECT-type E3
ubiquitin-ligase. However, when HUWE1 expression was knocked
down, ubiquitylation of the UFD substrate was still apparent
(Fig. 3c), suggesting that other cellular E3s also target the substrate.
We therefore decided to compare the effect of HUWE1 with that
of TRIP12.
Knock down of TRIP12 also led to a stabilization of the
UbG76V-YFP substrate (Fig. 3d). Again, the ubiquitylation pattern
of the UFD substrate did not appear to be affected. In double
knock down cells, lacking both HUWE1 and TRIP12, the stability
of the substrate was further increased (Fig. 3e), suggesting that
HUWE1 and TRIP12 function in parallel. However, since
ubiquitylation of the UFD substrate was still apparent (Fig. 3e),
the function of HUWE1 and TRIP12 must overlap with yet other
E3s.
Table 1. Significantly scoring genes.
Gene Protein Fisher’s combined p-values
PSMD14 proteasome 26S subunit, non-ATPase 14 2.1E-14
HUWE1 HECT, UBA and WWE domain containing 1 2.7E-06
PSMD7 proteasome 26S subunit, non-ATPase 7 0.0013
USP9X ubiquitin specific protease 9, X-linked 0.0014
UBE2L3 ubiquitin-conjugating enzyme, E2L3 0.0014
WSB1 WD repeat and SOCS box-containing 1 0.012
FBXL21 F-box and leucine-rich repeat protein 21 0.014
TRAF3 TNF receptor-associated factor 3 0.018
BRCC2 BRCC2 0.019
RNF187 ring finger protein 187 0.024
RNF169 ring finger protein 169 0.026
C13orf7 chromosome 13 open reading frame 7 0.028
USP41 ubiquitin specific protease 41 0.028
MGC48332 membrane-associated ring finger (C3HC4) 3 0.029
HECTD1 HECT domain containing 1 0.032
TRAF2 TNF receptor-associated factor 2 0.032
FBXO42 F-box protein 42 0.033
CBLL1 Cas-Br-M 0.042
RNF19 ring finger protein 19 0.043
doi:10.1371/journal.pone.0050548.t001
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HUWE1 Associates with both the UFD Substrate and the
26S Proteasome
If HUWE1 directly regulates the degradation of UbG76V-YFP,
the two components should at least transiently form an enzyme-
substrate complex. To test this prediction, we performed immuno-
precipitation experiments with the UbG76V-YFP substrate from
cells treated with MG132. The precipitates were resolved by SDS-
PAGE and analyzed by Western blotting. Probing the blots with
antibodies to GFP revealed that the UbG76V-YFP substrate was
precipitated, but not present in the negative controls (Fig. 4a).
During the course of these experiments, we also tested if 26S
proteasomes associate with HUWE1. When immuno-precipitating
the 26S proteasome, we observed that HUWE1 specifically co-
precipitated (Fig. 4b).
HUWE1 Stimulates Degradation of UBB+1
So far, the ubiquitin mutant UBB+1 constitutes the only
physiologically relevant substrate of the UFD pathway [11]. In
order to determine if HUWE1 also plays a role in UBB+1
degradation, the turnover of flag-tagged UBB+1 was followed in
cultures treated with the translation inhibitor cycloheximide
(CHX). UBB+1 was rapidly degraded in cells transfected with
control siRNA and stabilized upon knock down of HUWE1 and
TRIP12 (Fig. 5), revealing that HUWE1 also partakes in the
degradation of UBB+1.
Figure 3. HUWE1 and TRIP12 are required for UbG76V-YFP degradation. (a) Efficient knock down of HUWE1 was validated by Western
blotting, while for TRIP12 knock down was validated by RT-PCR. Actin and GAPDH served as loading controls. (b) The steady state level of the UbG76V-
YFP substrate was determined in cultures by blotting with antibodies to GFP. Actin served as a loading control. (c) Pulse-chase analyses of UbG76V-YFP
degradation in cells transfected with control siRNA or siRNA specific for HUWE1. (d) Pulse-chase analyses of UbG76V-YFP degradation in cells
transfected with control siRNA or siRNA specific for TRIP12. (e) Pulse-chase analyses of UbG76V-YFP degradation in cells transfected with control siRNA
or siRNA specific for TRIP12 and HUWE1.
doi:10.1371/journal.pone.0050548.g003
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Discussion
Bioinformatic analyses have shown that a significant fraction of
the eukaryotic genome is dedicated to the UPS, in some species
occupying as much as 5% of the genome [21]. This large number
of genes of the UPS is mainly attributed to the many different E3
ubiquitin-protein ligases [21] that are the major factors in
determining the specificity in conjugation of ubiquitin to target
proteins. Since the human genome is predicted to encode more
than 600 distinct E3s, the substrate specificity of the system should
at least be of a similar diversity. A major challenge is to link the
E3s with their respective substrate classes. This is not a trivial task,
which is further complicated by a significant amount of cross talk
between the degradation pathways. Thus, several proteins are
ubiquitylated by different E3s. For instance, p53 is ubiquitylated
by multiple E3s, including Mdm2, Hrd1/Synoviolin and CHIP
[22].
In the present study, we utilized high-throughput cellular
imaging on cells transfected with a targeted siRNA library to
screen for components involved in degradation of ubiquitin fusion
proteins. This is a powerful tool for studying gene function and
mapping biochemical pathways, which has recently been success-
fully applied to study various aspects of ubiquitin-dependent
protein degradation, including identification of protein quality
control factors [23].
The success of the screen was readily apparent since two
proteasome subunits PSMD7 and PSMD14 appeared as highly
significant hits. Our targeted siRNA library did not include any
other proteasome subunits, but presumably knockdown of most
proteasome subunits would interfere with the UFD pathway. The
second best scoring hit was the HECT-type E3 ubiquitin-protein
ligase HUWE1 (also known as ARF-BP1, Mule, HECTH9,
E3Histone, LASU1 and UREB1), recently connected with X-
linked mental retardation [24]. Since we could co-precipitate
HUWE1 with the UbG76V-YFP model substrate, we suggest that
HUWE1 directly ubiquitylates this protein for subsequent
degradation. Several HUWE1 targets, including signaling proteins
[25–26] and core histones [27], have previously been identified,
but this is the first demonstration of HUWE1 functioning in the
UFD pathway.
The E2 called UBE2L3 was another significant hit in our
screen. This is noteworthy since UBE2L3 (also known as UbcH7)
is an E2 enzyme which displays specificity for HECT type E3s and
has been reported to associate with HUWE1 [25] [28–29]. Studies
have shown that UBE2L3 functions as the cognate E2 for
HUWE1 catalyzed ubiquitylation of the anti-apoptotic Mcl-1
protein [25]. It is therefore possible that UBE2L3 functions as E2
enzyme in the UFD pathway.
In pulse-chase analyses, knock down of HUWE1 and the
human orthologue of Ufd4, TRIP12, led to a comparable
stabilization of the UFD substrate. In addition to the C-terminal
HECT domains, both HUWE1 and TRIP12 also contain WWE
domains [3], but do otherwise not share sequence similarity.
However, since studies have shown that the TRIP12 HECT
domain alone can mediate degradation of UFD substrates [11] it is
possible that other HECT-type E3s will function in a similar
fashion. TRIP12 was not included in our siRNA library, but
indeed we note that another HECT domain E3, HECTD1
(Fig. 2b), was a significant hit in our screen. However, various
RING-type E3s also scored significantly, while several other
HECT domain E3s, included in the siRNA library, failed to score.
Since the UFD pathway is phylogenetically conserved in
eukaryotes [8], it is surprising that UBB+1 so far is the only
Figure 4. HUWE1 is associated with UbG76V-YFP and the 26S proteasome. (a) Immuno precipitates (IP) of the UbG76V-YFP substrate using
either control antibodies or antibodies to GFP from cultures transfected to express UbG76V-YFP (left panel) or as a control mock transfectants (right
panel). The precipitates were analyzed by blotting with antibodies to HUWE1 and GFP. (b) 26S proteasomes were immunoprecipitated from MelJuSo
cells using antibodies to Rpn10 and analyzed by blotting with antibodies to HUWE1 and the 26S proteasome subunits Rpn10 and Rpt2.
doi:10.1371/journal.pone.0050548.g004
Figure 5. HUWE1 is required for UBB+1 degradation. The degradation of flag tagged UBB+1 was followed by blotting of cultures treated with
cycloheximide (CHX) for the indicated times. Actin served as a loading control.
doi:10.1371/journal.pone.0050548.g005
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known UFD substrate, which is physiologically relevant. However,
HUWE1 has recently been shown to catalyze N-terminal (a-
amino) ubiquitylation, thus forming linear ubiquitin fusion
proteins [26]. It is therefore conceivable that HUWE1 and other
E3 ligases in this manner generate natural UFD substrates.
Previous studies have shown that TRIP12 mediates ubiquityla-
tion and degradation of UBB+1 [11], and our data show that this
function is shared with HUWE1. However, in comparison with
TRIP12 the effect of HUWE1 shown here appears more
moderate. Previously, a proteomics study found that HUWE1
associates with 26S proteasomes from brain tissue [30]. We also
found that HUWE1 co-precipitates with 26S proteasomes,
suggesting it might function at a rather late step in the degradation
pathway, where perhaps several degradation pathways converge.
Given that HUWE1 contains several ubiquitin binding domains it
is possible that it may display specificity for already ubiquitylated
substrates and could therefore function in ubiquitin chain
elongation similar to the E4 Ufd2 [2].
Supporting Information
Figure S1 siRNA Library Overview. The figure depicts the
layout of the siRNA library plates utilized.
(TIF)
Figure S2 siRNA screen performance. Overall screen
performance based on the percentage of UbG76V-YFP positive
cells in non-silencing control (N), positive control p97 (P) and
individual siRNAs from the screening library (S). Percentages were
plate-wise normalized and arcsinh transformed for better clarity.
(TIF)
Table S1 Statistical analyses of the siRNA screens. P-
values of the three individual screens combined to a common p-
value based on Fisher’s probability test for all library targets.
(XLS)
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